Eli Lilly Ai Drug Design

Lilly, Weight Loss Pill

From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Reuters · 14d

Lilly reassures investors that weight-loss drug demand is strong, shares rise

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Business Insider · 7h

Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the

Quartz on MSN · 9h

Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the world. Now, the pharma giant wants to reinvest its success with weight-loss meds into tackling some of the world’s toughest health challenges.

Seeking Alpha on MSN · 10h

Lilly's next obesity drug serves up dramatic weight loss -- and side effects - report

Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, it has also come with its share of notable side effects.

Benzinga.com1mon

Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases

Isomorphic Labs, spun out from Google DeepMind in 2021, represents a growing trend of tech giants leveraging AI to streamline the traditionally lengthy and expensive drug development process.

pharmaphorum6d

Lilly takes AI-selected Olumiant into phase 3 for COVID-19

Eli Lilly has enrolled the first patient into a phase 3 trial that is seeking to repurpose arthritis drug Olumiant as a treatment for people with COVID-19. The 400-patient trial will test ...

FierceBiotech10d

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Nasdaq23d

AI Pharma: 2 Paths to AI-Powered Drug Investment

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence (AI). Traditionally, drug development ... by Eli Lilly (NYSE: LLY ...

AOL10d

Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals

Also Read: Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years In 2023, Eli Lilly acquired POINT Biopharma Global at $12.50 per ...

NBC Washington14d

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results